Aringhieri S et al (2018) Molecular targets of atypical antipsychotics: from mechanism of action to clinical differences. Pharmacol Ther 192:20–41

Article  CAS  PubMed  Google Scholar 

Brisman MH, Fetell MR, Post KD (1993) Reversible dementia due to macroprolactinoma. Case report. J Neurosurg 79(1):135–137

Article  CAS  PubMed  Google Scholar 

Degl’Innocenti A et al (1999) The influence of prolactin response to d-fenfluramine on executive functioning in major depression. Biol Psychiatry 46(4):512–517

Article  CAS  PubMed  Google Scholar 

Fan F et al (2019) Subcortical structures and cognitive dysfunction in first episode schizophrenia. Psychiatry Res Neuroimaging 286:69–75

Article  PubMed  PubMed Central  Google Scholar 

Fitzgerald P, Dinan TG (2008) Prolactin and dopamine: what is the connection? A review article. J Psychopharmacol 22(2 Suppl):12–19

Article  PubMed  Google Scholar 

García RR, Aliste F, Soto G (2018) Social cognition in schizophrenia: cognitive and neurobiological aspects. Rev Colomb Psiquiatr (engl Ed) 47(3):170–176

PubMed  Google Scholar 

Hagi K et al (2021) Association between cardiovascular risk factors and cognitive impairment in people with schizophrenia: a systematic review and meta-analysis. JAMA Psychiat 78(5):510–518

Article  Google Scholar 

Havelka D et al (2016) Cognitive impairment and cortisol levels in first-episode schizophrenia patients. Stress 19(4):383–389

Article  CAS  PubMed  Google Scholar 

Herceg M et al (2020) Correlation between prolactin and symptom profile in acute admitted women with recurrent schizophrenia. Psychiatr Danub 32(3–4):367–372

Article  CAS  PubMed  Google Scholar 

Ittig S et al (2017) Sex differences in prolactin levels in emerging psychosis: indication for enhanced stress reactivity in women. Schizophr Res 189:111–116

Article  PubMed  Google Scholar 

Jones AS et al (2021) Prolactin ordering patterns in psychiatric inpatients and the impact this has on patient management. Australas Psychiatry 29(3):282–285

Article  PubMed  Google Scholar 

Jose J et al (2015) Association between prolactin and thyroid hormones with severity of psychopathology and suicide risk in drug free male schizophrenia. Clin Chim Acta 444:78–80

Article  CAS  PubMed  Google Scholar 

Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13(2):261–276

Article  CAS  PubMed  Google Scholar 

Labad J (2019) The role of cortisol and prolactin in the pathogenesis and clinical expression of psychotic disorders. Psychoneuroendocrinology 102:24–36

Article  CAS  PubMed  Google Scholar 

Lim K et al (2021) Large-scale evaluation of the Positive and Negative Syndrome Scale (PANSS) symptom architecture in schizophrenia. Asian J Psychiatr 62:102732

Article  PubMed  Google Scholar 

Marken PA, Haykal RF, Fisher JN (1992) Management of psychotropic-induced hyperprolactinemia. Clin Pharm 11(10):851–856

CAS  PubMed  Google Scholar 

McGregor C, Riordan A, Thornton J (2017) Estrogens and the cognitive symptoms of schizophrenia: Possible neuroprotective mechanisms. Front Neuroendocrinol 47:19–33

Article  CAS  PubMed  Google Scholar 

Miller R (2009) Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: part I. Curr Neuropharmacol 7(4):302–314

Article  CAS  PubMed  PubMed Central  Google Scholar 

Montalvo I et al (2014) Increased prolactin levels are associated with impaired processing speed in subjects with early psychosis. PLoS One 9(2):e89428

Article  PubMed  PubMed Central  Google Scholar 

Montalvo I et al (2018) Improvement in cognitive abilities following cabergoline treatment in patients with a prolactin-secreting pituitary adenoma. Int Clin Psychopharmacol 33(2):98–102

Article  PubMed  Google Scholar 

Moore L et al (2013) Serum testosterone levels are related to cognitive function in men with schizophrenia. Psychoneuroendocrinology 38(9):1717–1728

Article  CAS  PubMed  Google Scholar 

Mortimer AM (2007) Relationship between estrogen and schizophrenia. Expert Rev Neurother 7(1):45–55

Article  CAS  PubMed  Google Scholar 

Penadés R et al (2015) The search for new biomarkers for cognition in schizophrenia. Schizophr Res Cogn 2(4):172–178

Article  PubMed  PubMed Central  Google Scholar 

Puljic K et al (2021) The association between prolactin concentration and aggression in female patients with schizophrenia. World J Biol Psychiatry 22(4):301–309

Article  CAS  PubMed  Google Scholar 

Rajkumar RP (2014) Prolactin and psychopathology in schizophrenia: a literature review and reappraisal. Schizophr Res Treat 2014:175360

Google Scholar 

Sheffield JM, Karcher NR, Barch DM (2018) Cognitive deficits in psychotic disorders: a lifespan perspective. Neuropsychol Rev 28(4):509–533

Article  PubMed  PubMed Central  Google Scholar 

Shi C et al (2013) An ecologically valid performance-based social functioning assessment battery for schizophrenia. Psychiatry Res 210(3):787–793

Article  PubMed  Google Scholar 

Shi C et al (2015) The MATRICS Consensus Cognitive Battery (MCCB): co-norming and standardization in China. Schizophr Res 169(1–3):109–115

Article  PubMed  PubMed Central  Google Scholar 

Shi C et al (2019) What is the optimal neuropsychological test battery for schizophrenia in China? Schizophr Res 208:317–323

Article  PubMed  PubMed Central  Google Scholar 

Voráčková V et al (2021) Cognitive profiles of healthy siblings of first-episode schizophrenia patients. Early Interv Psychiatry 15(3):554–562

Article  PubMed  Google Scholar 

Vuk Pisk S et al (2019) Hyperprolactinemia—side effect or part of the illness. Psychiatr Danub 31(Suppl 2):148–152

PubMed  Google Scholar 

Wasnik V et al (2019) Serum prolactin level and its correlation with psychopathology in drug free/drug naïve schizophrenia a case control study. Asian J Psychiatr 39:1–5

Article  PubMed  Google Scholar 

Yao S et al (2017) Cognitive function and serum hormone levels are associated with gray matter volume decline in female patients with prolactinomas. Front Neurol 8:742

Article  PubMed  Google Scholar 

Zhang XY et al (2002) Risperidone-induced increase in serum prolactin is correlated with positive symptom improvement in chronic schizophrenia. Psychiatry Res 109(3):297–302

Article  CAS  PubMed  Google Scholar 

Zhang X et al (2020) Glucose disturbances, cognitive deficits and white matter abnormalities in first-episode drug-naive schizophrenia. Mol Psychiatry 25(12):3220–3230

Article  CAS  PubMed  Google Scholar 

Zhu MH et al (2022) Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial. Mil Med Res 9(1):59

CAS  PubMed  PubMed Central  Google Scholar